In one paragraphArticle in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
23 authors.
Pirmin SchlickeDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-9619-728X Caner ErcanInstitute for Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-5611-2699 Sara RanjbarInstitute for Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-4344-1282 Ashlee N SeldomridgeDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-9635-5006 Sadhna AggarwalDepartment of Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-4646-9352 Adwait MehtaDepartment of Hospital Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Tania P SainzDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0009-0002-1476-5680 Mohammad U ZahidDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0003-4893-4462 Penny FangDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Veronika A HofmannSchool of Computation, Information and Technology, Technical University of Munich, Munich, Germany.ORCID 0009-0003-5237-7133 Tatiana Cisneros NapravnikDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Nahum Puebla-OsorioDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-6498-5230 Christina KuttlerSchool of Computation, Information and Technology, Technical University of Munich, Munich, Germany.ORCID 0000-0002-5521-4159 Ann KloppDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Lauren ColbertDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-5806-4339 Ashley M HolderDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-6506-5871 Roi WeiserDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-4522-6404 Steven H LinDepartment of Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Carlos A Torres-CabalaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-7422-0661 Francisco VegaDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-5956-452X Yinyin YuanInstitute for Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Heiko EnderlingDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-9696-6410 Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MTRAINING OF ACADEMIC SURGICAL ONCOLOGISTST32CA009599 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Ashley M Holder, Jennifer A. Wargo · 1988 to 2026
$13.2MProject 4 Green-DavisP01CA272295 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Leandro C Cerchietti, CHRISTOPHER R FLOWERS · 2024 to 2026
$9.3MProject 3: AI Digital Pathology Tools to Address Disparities in Lymphoma Diagnosis and Classification for Underserved CommunitiesU54CA302435 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHRISTOPHER R FLOWERS, JEAN L KOFF · 2025 to 2026
$7.4MNCI NIH HHS P01 CA272295NCI NIH HHS P30 CA016672NCI NIH HHS T32 CA009599NCI NIH HHS U54 CA302435
6 · The paper itselfAbstract
Routine H&E-histopathology captures spatial snapshots of tumor ecosystems, yet computational pathology largely treats them as textures without explicit links to underlying kinetics. We show that patient-specific parameters of a mechanistic reaction-diffusion model can be inferred from a single biopsy. Cell-nucleus point patterns are fitted jointly to the analytical two-point correlation function and power spectral density, recovering patient-specific mechanistic proliferation and diffusion rates across eleven multicenter cohorts. Derived dispersion length and front velocity define mechanistic phenotypes stratifying progression-free and overall survival and adding information independent of routine covariates. We illustrate counterfactual radiotherapy simulations in glioblastoma and show that a virtual clinical trial deescalating histology-calibrated faster-growing tumors to hypofractionation while dose-intensifying slower-growing tumors adds 96.7 days of restricted mean progression-free
Indexed as
Histopathologymechanistic modelingpower spectral densitypredictive oncologyreaction-diffusion equationspatial point patterntwo-point correlation function
Identifiers
PMID42818877
PMCPMC13622794
What OpenQuestion holds
Textmetadata
Read underepoch 390